US 12365719
CD80 extracellular domain polypeptides and their use in cancer treatment
granted A61KA61K2039/505A61K38/00
Quick answer
US patent 12365719 (CD80 extracellular domain polypeptides and their use in cancer treatment) held by Five Prime Therapeutics, Inc. expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Five Prime Therapeutics, Inc.
- Grant date
- Tue Jul 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 18
- CPC classes
- A61K, A61K2039/505, A61K38/00, A61K38/1774, A61K39/39558